The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Nvidia sold its entire 7.71 million share stake in Recursion Pharmaceuticals by December 31, 2025 Recursion stock swung 14% lower intraday Wednesday before closing 2% higher ARK Invest bought 1.25 ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Visualize recursion in real-time — watch the call stack grow & shrink with stack and tree views. Built with HTML, CSS, JS (Canvas).

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. The analyst who called NVIDIA in 2010 just named his top ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...